266 related articles for article (PubMed ID: 25496233)
41. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
42. Activation of BK(Ca) channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells.
Ma YG; Liu WC; Dong S; Du C; Wang XJ; Li JS; Xie XP; Wu L; Ma DC; Yu ZB; Xie MJ
PLoS One; 2012; 7(5):e37451. PubMed ID: 22655048
[TBL] [Abstract][Full Text] [Related]
43. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.
Wilson C; Ottewell P; Coleman RE; Holen I
BMC Cancer; 2015 Feb; 15():55. PubMed ID: 25884855
[TBL] [Abstract][Full Text] [Related]
44. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
[TBL] [Abstract][Full Text] [Related]
45. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
46. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.
Räikkönen J; Taskinen M; Dunford JE; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Biophys Res Commun; 2011 Apr; 407(4):663-7. PubMed ID: 21420384
[TBL] [Abstract][Full Text] [Related]
47. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
48. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.
Dedes PG; Gialeli Ch; Tsonis AI; Kanakis I; Theocharis AD; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2012 Dec; 1820(12):1926-39. PubMed ID: 22884656
[TBL] [Abstract][Full Text] [Related]
49. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
Li J; Rugo HS
Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
[TBL] [Abstract][Full Text] [Related]
50. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Fisher JE; Rodan GA; Reszka AA
Endocrinology; 2000 Dec; 141(12):4793-6. PubMed ID: 11108295
[TBL] [Abstract][Full Text] [Related]
51. Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.
Gschwantler-Kaulich D; Weingartshofer S; Grunt TW; Mairhofer M; Tan Y; Gamper J; Singer CF
PLoS One; 2017; 12(9):e0185566. PubMed ID: 28945801
[TBL] [Abstract][Full Text] [Related]
52. Novel triterpenoid 25-hydroxy-3-oxoolean-12-en-28-oic acid induces growth arrest and apoptosis in breast cancer cells.
Rabi T; Wang L; Banerjee S
Breast Cancer Res Treat; 2007 Jan; 101(1):27-36. PubMed ID: 17028990
[TBL] [Abstract][Full Text] [Related]
53. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.
Ibrahim T; Liverani C; Mercatali L; Sacanna E; Zanoni M; Fabbri F; Zoli W; Amadori D
Int J Oncol; 2013 Apr; 42(4):1263-70. PubMed ID: 23403907
[TBL] [Abstract][Full Text] [Related]
54. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
Hirbe AC; Roelofs AJ; Floyd DH; Deng H; Becker SN; Lanigan LG; Apicelli AJ; Xu Z; Prior JL; Eagleton MC; Piwnica-Worms D; Rogers MJ; Weilbaecher K
Bone; 2009 May; 44(5):908-16. PubMed ID: 19442620
[TBL] [Abstract][Full Text] [Related]
55. Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
Inoue S; Arai N; Tomihara K; Takashina M; Hattori Y; Noguchi M
Eur J Pharmacol; 2015 Aug; 761():44-54. PubMed ID: 25934567
[TBL] [Abstract][Full Text] [Related]
56. Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.
Tardoski S; Ngo J; Gineyts E; Roux JP; Clézardin P; Melodelima D
Sci Rep; 2015 Nov; 5():16354. PubMed ID: 26578234
[TBL] [Abstract][Full Text] [Related]
57. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
58. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines.
Witters LM; Crispino J; Fraterrigo T; Green J; Lipton A
Am J Clin Oncol; 2003 Aug; 26(4):S92-7. PubMed ID: 12902864
[TBL] [Abstract][Full Text] [Related]
59. Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells.
Kucukzeybek Y; Gorumlu G; Cengiz E; Karabulut B; Sezgin C; Atmaca H; Sanli UA; Uzunoglu S; Uslu R
J Int Med Res; 2010; 38(5):1663-72. PubMed ID: 21309480
[TBL] [Abstract][Full Text] [Related]
60. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
